|
HBV |Abstract Library |
|
|
The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors. |
Abstract Details |
|
|
|
|
|
|
|
|
Assay for Hepatitis B Core-related Antigen Identify Patients With High Viral Load: Systematic Review and Meta-analysis of Individual Participant Data |
|
|
|
|
|
Clin Gastroenterol Hepatol. 2020 Apr 29;S1542-3565(20)30590-5.doi: 10.1016/j.cgh.2020.04.045. Online ahead of print.
Kyoko Yoshida 1, Alice Desbiolles 2, Sarah F Feldman 2, Sang Hoon Ahn 3, Enagnon K Alidjinou 4, Masanori Atsukawa 5, Laurence Bocket 4, Maurizia R Brunetto 6, Maria Buti 7, Ivana Carey 8, Gian Paolo Caviglia 9, En-Qiang Chen 10, Markus Cornberg 11, Masaru Enomoto 12, Masao Honda 13, Christoph Höner Zu Siederdissen 11, Masatoshi Ishigami 14, Harry LA Janssen 15, Benjamin Maasoumy 11, Takeshi Matsui 16, Akihiro Matsumoto 17, Shuhei Nishiguchi 18, Mar Riveiro-Barciela 7, Akinobu Takaki 19, Pisit Tangkijvanich 20, Hidenori Toyoda 21, Margo Jh van Campenhout 22, Bo Wang 8, Lai Wei 23, Hwai-I Yang 24, Yoshihiko Yano 25, Hiroshi Yatsuhashi 26, Man-Fung Yuen 27, Eiji Tanaka 28, Maud Lemoine 1, Yasuhito Tanaka 29, Yusuke Shimakawa 30
|
|
|
|
|
Author information
- 1Department of Surgery and Cancer, Liver Unit, Imperial College London, Praed St, Paddington, London W2 1NY, UK.
- 2Unité d'Épidémiologie des Maladies Émergentes, Institut Pasteur, 25-28 Rue du Dr Roux, 75015 Paris, France.
- 3Department of Internal Medicine, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 120-752, Korea.
- 4Laboratoire de Virologie, Centre de Biologie Pathologie, CHU de Lille, Boulevard du Professeur Jules Leclercq, 59037 Lille, France.
- 5Division of Gastroenterology, Department of Internal Medicine, Nippon Medical School Chiba Hokusoh Hospital, 1715 Kamakari, Inzai, Chiba 270-1694, Japan.
- 6Hepatology Unit and Laboratory of Molecular Genetics and Pathology of Hepatitis Viruses, University Hospital of Pisa, Lungarno Antonio Pacinotti, 43, 56126 Pisa PI, Italy.
- 7Liver Unit, Department of Internal Medicine, Hospital Universitari Vall d'Hebron and Universitat Autònoma de Barcelona, Passeig Vall Hebron, 119-129, 08035, Barcelona, Spain.
- 8Institute of Liver Studies, King's College Hospital, Denmark Hill, Brixton, London SE5 9RS, UK.
- 9Department of Medical Sciences, University of Turin, Corso Dogliotti 14, Turin 10126, Italy.
- 10Center of Infectious Diseases, West China Hospital, Sichuan University, No. 37 Guo Xue Xiang, Wuhou District, Chengdu 610041, China.
- 11Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Carl-Neuberg Strasse 1, 30625 Hannover, Germany.
- 12Department of Hepatology, Graduate School of Medicine, Osaka City University Medical School, 1-4-3 Asahimachi, Abeno-ku, Osaka 545-8585, Japan.
- 13Department of Gastroenterology, and Department of Advanced Medical Technology, Kanazawa University Graduate School of Health Medicine, 13-1 Takara-Machi, Kanazawa, Ishikawa 920-8641, Japan.
- 14Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, 65 Tsuruma-cho, Showa-ku, Nagoya 466-8550, Japan.
- 15Toronto Centre for Liver Disease, Toronto General Hospital, University Of Toronto, 200 Elizabeth Street, Eaton Building 9th floor Room 234 (9EB234), Toronto, ON, Canada.
- 16Center for Gastroenterology, Teine-Keijinkai Hospital, 12-1-40 Maeda-ichijo, Teine, Sapporo, Hokkaido 006-0811, Japan.
- 17Department of Internal Medicine, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto 390-8621, Japan.
- 18Division of Hepatobiliary and Pancreatic Disease, Department of Internal Medicine, Hyogo College of Medicine, 1-1 Mukogawacho, Nishinomiya, Hyogo 663-8501, Japan.
- 19Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Okayama 700-8558, Japan.
- 20Center of Excellence in Hepatitis and Liver cancer, Faculty of Medicine, Chulalongkorn University, 1873 Rama IV Rd, 10330, Bangkok, Thailand.
- 21Department of Gastroenterology and Hepatology, Ogaki Municipal Hospital, 4-86 Minaminokawa, Ogaki, Gifu 503-8502, Japan.
- 22Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Doctor Molewaterplein 40, 3015 GD Rotterdam, The Netherlands.
- 23Peking University Hepatology Institute, Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases, Peking University People's Hospital, No. 11 Xizhimen South Street, Beijing 100044, China.
- 24Genomics Research Center, Academia Sinica, 128 Academia Road, Nankang, Taipei 11529, Taiwan.
- 25Center for Infectious Diseases, Department of Gastroenterology, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan.
- 26Clinical Research Center, National Hospital Organization (NHO), Nagasaki Medical Center, 2-1001-1, Kubara, Omura, Nagasaki 856-8562, Japan.
- 27Department of Medicine, The University of Hong Kong, Queen Mary Hospital, 102 Pokfulam Road, Hong Kong, China.
- 28Department for the Promotion of Regional Medicine, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto 390-8621, Japan.
- 29Department of Virology and Liver Unit, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho, Nagoya 467-8601, Japan.
- 30Unité d'Épidémiologie des Maladies Émergentes, Institut Pasteur, 25-28 Rue du Dr Roux, 75015 Paris, France. Electronic address: yusuke.shimakawa@pasteur.fr.
Abstract
Background & aims: Scale-up of tests and treatments is needed to eliminate hepatitis B virus (HBV) infection from resource-limited countries. However, access to nucleic acid tests that quantify HBV DNA, to determine treatment eligibility, is severely limited. We performed a systematic review and meta-analysis to assess the performance of the hepatitis B core-related antigen (HBcrAg) immunoassay, a low-cost (less than $15/assay) alternative to the nucleic acid test, to identify highly viremic patients, infected with any HBV genotype.
Methods: We searched Medline, Embase, Scopus, and Web of Science through June 27, 2018 for studies that measured HBV DNA and HBcrAg in the same blood samples. We contacted study authors to obtain data from each study participant, and randomly assigned each participant to the derivation or validation cohorts. We applied optimal HBcrAg cut-off values derived from the derivation set to the validation set to estimate sensitivity and specificity of HBcrAg to indicate high viremia.
Results: Of 74 eligible studies found in the systematic review, we obtained individual participant data from 60 studies (81%). We performed a meta-analysis of individual participant data of 5591 HBV-infected patients who did not receive antiviral therapy and 4806 HBV-infected patients who received antiviral agents. In untreated patients, the pooled area under the receiver operating characteristic curve and the optimal cut-off value for the HBcrAg assay were 0.88 (95% CI, 0.83-0.94) and 3.6 log U/ml for identifying patients with a level of HBV DNA ≥2000 IU/ml, and 0.96 (95% CI, 0.94-0.98) and 5.3 log U/ml for identifying patients with a level of HBV DNA ≥200,000 IU/ml, respectively. In the validation set, the HBcrAg assay identified patients with ≥2000 IU/ml HBV DNA with 85.2% sensitivity and 84.7% specificity; the assay identified patients with ≥200,000 IU/ml HBV DNA with 91.8% sensitivity and 90.5% specificity. Performance did not vary among HBV genotypes. In patients receiving anti-HBV therapy, there was no correlation between levels of HBcrAg and HBV DNA.
Conclusions: In a systematic review and meta-analysis of individual participant data, we found that the assay for HBcrAg identifies treatment-naïve patients with high levels of HBV DNA with high sensitivity and specificity, regardless of genotype. The HBcrAg assay is a good, low-cost alternative to the nucleic acid test to identify highly viremic patients infected with different genotypes.
|
|
|
|
|
|
|
|
|
|
|
|
|